AstraZeneca investors raise concerns over mega-merger talks

6 hours ago

Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
Click here to Read More
Previous Article
AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough
Next Article
Republican holdouts say they will back Todd Blanche for attorney general

Related Finance Updates:

Are you sure? You want to delete this comment..! Remove Cancel

Comments (0)

    Leave a comment